Mechanistic studies have shown that niclosamide may exert its effect through degrading AR-Vs or through inhibiting other pathways, including AKT/mTOR/Pi3K, NF-κB, and Wnt-signaling, which are implicated in prostate cancer resistance and progression[17, 28–32]. This evidence concerns the gene AR and prostate cancer.